These findings confirmed the action of BAY-293 on the target and are consistent with preclinical studies that have demonstrated the effectiveness of BAY-293 in reducing KRAS signaling and tumor growth in cell lines and animal models [43,44,45]. Here, KRAS is linked to neoplasm.